Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition

JOIN US FOR AN EDUCATIONAL WEBINAR

Upcoming Webinars

Tuesday, June 4  
8:00 - 9:00 PM ET

5:00 - 6:00 PM PT

   

PRESENTERS

Jessica Steen, OD, FAAO
NOVA Southeastern
Fort Lauderdale, Florida

Karl G. Stonecipher, MD
University of North Carolina
Greensboro, NC

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

CLICK HERE for full Prescribing Information for MIEBO. 

 

 

INDICATION

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

CLICK HERE for full Prescribing Information for Xiidra.

Sponsored by

 

©2024 Bausch + Lomb   
MBO.0130.USA.24
All Information pertains to the U.S. only, unless otherwise indicated.

Brought to you by